Multi-Blood Monitoring System Market is expected to reach USD 3.9 billion by 2034, with a 6.4% CAGR growth
Multi Blood Monitoring System Market Overview 2025-2034
Luton, Bedfordshire, United Kingdom, June 10, 2025 (GLOBE NEWSWIRE) -- The global multi blood monitoring system market is witnessing dynamic expansion, with its value estimated at approximately USD 2.1 billion in 2024, and expected to grow to around USD 3.9 billion by 2034. This translates into a Compound Annual Growth Rate (CAGR) of 6.4% over the forecast period from 2025 to 2034. This growth is primarily fueled by the increasing demand for accurate, efficient, and accessible blood monitoring technologies across various healthcare applications.
Download PDF Brochure: https://exactitudeconsultancy.com/request-sample/65018
These devices are critical in the management of chronic diseases such as diabetes and cardiovascular conditions. As the global burden of such illnesses escalates, particularly among aging populations and across developing regions, the need for real-time, portable, and user-friendly blood monitoring systems has become more urgent than ever.
Market Drivers and Opportunities
Several underlying factors are contributing to the expansion of this market. Among the most significant drivers is the rising prevalence of chronic diseases. The World Health Organization (WHO) forecasts that by 2030, chronic diseases will account for over 75% of global deaths, highlighting the growing necessity for continuous and reliable health monitoring tools.
Moreover, technological advancements in wearable devices, mobile health apps, and telemedicine have revolutionized the way blood monitoring is conducted. These innovations have led to more personalized and preventive healthcare solutions, allowing patients to self-monitor in real-time, often without the need for clinical supervision. This trend is particularly appealing to tech-savvy consumers and younger demographics who are increasingly proactive about their health.
Emerging economies also present significant growth potential. With rising healthcare expenditure, expanding middle-class populations, and improving medical infrastructure, regions such as Asia-Pacific, Latin America, and parts of the Middle East are becoming fertile grounds for market expansion. Additionally, the integration of AI and machine learning into monitoring systems is creating opportunities for predictive diagnostics and tailored treatment strategies, revolutionizing the future of personalized medicine.
Key Market Challenges
Despite its positive growth outlook, the multi blood monitoring system market faces certain challenges. One of the primary obstacles is the complex regulatory landscape. Medical device manufacturers must navigate stringent approval processes, especially in developed regions like North America and Europe. These regulations, although necessary for ensuring safety and efficacy, often delay product rollouts and increase development costs.
Supply chain disruptions have also impacted the market, particularly during and after the COVID-19 pandemic. Delays in procuring raw materials, component shortages, and transportation hurdles have affected production timelines and product availability.
Furthermore, high costs associated with technologically advanced blood monitoring devices can be a deterrent for adoption, especially in price-sensitive markets. Healthcare providers are often pressured to deliver cost-effective solutions, which can limit investments in premium monitoring systems.
Another pressing concern is data security and patient privacy. With the growing digitalization of healthcare and increased reliance on cloud-based data storage, ensuring the protection of sensitive patient information has become paramount. Regulatory frameworks such as HIPAA and GDPR are placing additional burdens on companies to fortify their cybersecurity measures.
Market Segmentation Analysis
By Product Type
The market is segmented into several product categories including continuous glucose monitoring (CGM) systems, blood pressure monitors, cholesterol testing devices, and complete blood count (CBC) test devices. Among these, CGM systems are emerging as the dominant product category, accounting for roughly 35% of market share. The increased prevalence of diabetes globally has significantly contributed to this trend.
Blood pressure monitoring devices come in second, capturing an estimated 25% of the market, owing to the widespread incidence of hypertension. Cholesterol testing devices follow with a 15% market share, as more individuals become aware of the risks associated with high cholesterol levels.
By End User
Hospitals are the largest consumers of multi blood monitoring systems, accounting for nearly 45% of the market share. The growing number of patients and a strong focus on preventive healthcare are driving demand in this segment. Diagnostic laboratories represent the second-largest user group, contributing 30% of market revenue, largely due to the complexity and volume of testing they handle.
Homecare settings have gained traction, especially post-pandemic, and currently hold around 20% of the market. The convenience of remote monitoring has been widely appreciated, particularly among the elderly and chronically ill patients who prefer in-home testing.
By Technology
From a technology standpoint, wearable technologies are transforming the landscape, projected to represent 40% of the market by 2034. These devices offer unmatched convenience and user engagement. Invasive technologies still maintain a solid 45% market share, particularly in clinical environments where precision is critical. Meanwhile, non-invasive technologies are growing steadily and are expected to hold 15% of the market, driven by advancements in optical and sensor-based innovations.
By Application
Diabetes management remains the top application area, constituting about 50% of the total market. As diabetes rates continue to climb worldwide, the demand for continuous and accurate glucose monitoring devices is increasing proportionally. Cardiovascular monitoring is another important application, making up 30% of the market, while fitness and wellness monitoring is growing rapidly, accounting for around 15% as consumers adopt proactive health strategies.
By Distribution Channel
In terms of distribution, offline sales still dominate with a 55% market share, primarily due to the preference for in-person consultations and product demonstrations in hospital and clinical settings. Online channels, however, are growing fast and now represent 30% of sales, fueled by digital adoption and e-commerce growth. Direct sales—through specialized distributors—comprise the remaining 15%, ensuring product customization and support services.
Browse full Report - https://exactitudeconsultancy.com/reports/65018/global-multi-blood-monitoring-system-market
Market Segmentation
Product Type - Continuous Glucose Monitoring Systems - Blood Pressure Monitoring Devices - Cholesterol Testing Devices - Complete Blood Count Test Devices - Others
End-User - Hospitals - Diagnostic Laboratories - Homecare Settings - Research Institutions
Technology - Wearable Technology - Non-invasive Technology - Invasive Technology
Application - Diabetes Management - Cardiovascular Monitoring - Blood Disorders Management - Fitness and Wellness Monitoring
Distribution Channel - Online Sales - Offline Sales - Direct Sales
Region - North America - Europe - Asia Pacific - Latin America - Middle East & Africa
Regional Outlook
Regionally, North America leads the global market, accounting for approximately 40% of total revenues in 2024. This dominance is attributed to advanced healthcare infrastructure, favorable regulatory support, and the presence of leading industry players. Europe follows with a 30% market share, supported by robust public healthcare systems and a rising focus on personalized medicine.
The Asia-Pacific region is the fastest-growing market, projected to expand at a CAGR of 7.5%. This growth is driven by large patient populations, increasing disposable income, and government initiatives to enhance healthcare access. Countries such as China, India, and Japan are key contributors to this growth trajectory.
Latin America and the Middle East & Africa collectively account for a modest share (5% in 2024) but are poised for steady growth due to improvements in healthcare infrastructure and expanding awareness about chronic disease management.
Key Competitors
Abbott Laboratories
Roche Holding AG
Siemens Healthineers
Becton, Dickinson and Company (BD)
Medtronic plc
Nova Biomedical
Johnson & Johnson
Dexcom, Inc.
Arkray, Inc.
Ascensia Diabetes Care
Terumo Corporation
GlySens Incorporated
Insulet Corporation
Elysium Health
LabCorp
Recent Industry Developments
Several companies have made notable strides in advancing this market:
Abbott Laboratories launched FreeStyle Libre 3, a real-time glucose monitor with a discreet sensor, in June 2023, strengthening its lead in the CGM space.
In April 2023, Roche formed a strategic partnership with a wearable tech firm to integrate blood monitoring devices with smart devices, enhancing patient engagement and adherence.
Siemens Healthineers acquired an AI-based diagnostics company in August 2023, signaling a deeper focus on precision diagnostics through data analytics.
Dexcom received FDA approval in September 2023 for a no-fingerstick CGM device, which is likely to broaden its user base and redefine market standards.
Medtronic expanded its product line into Asia and Africa in July 2023, targeting underserved markets and accelerating growth in emerging economies.
This report is also available in the following languages : Japanese (マルチ血液モニタリングシステム市場), Korean (다혈액 모니터링 시스템 시장), Chinese (多血液监测系统市场), French (Marché des systèmes de surveillance sanguine multi-sang), German (Markt für Multi-Blutüberwachungssysteme), and Italian (Mercato dei sistemi di monitoraggio multi-sangue), etc.
Request Sample Pages: https://exactitudeconsultancy.com/reports/65018/global-multi-blood-monitoring-system-market#request-a-sample
More Research Finding –
Medical Refrigerated Market
The global medical refrigerated market is valued at approximately $6.5 billion in 2024, with projections indicating a potential increase to around $10 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of approximately 4.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66520/medical-refrigerated-market
Cardiovascular Monitoring Devices Market
The cardiovascular monitoring devices market is valued at approximately $10.5 billion in 2024, with projections indicating substantial growth, reaching around $16.8 billion by 2034. This translates to a robust Compound Annual Growth Rate (CAGR) of approximately 4.8% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66470/cardiovascular-monitoring-devices-market
Non Invasive Hemodynamic Detection System Market
The global Non-Invasive Hemodynamic Detection System market is valued at approximately USD 2.1 billion in 2024, with strong growth anticipated over the next decade. By 2034, the market is projected to reach around USD 4.5 billion, representing a Compound Annual Growth Rate (CAGR) of approximately 8.0%.
https://exactitudeconsultancy.com/reports/66463/non-invasive-hemodynamic-detection-system-market
Disposable Syringes and Accessories Market
The global disposable syringes and accessories market is valued at approximately $7.5 billion in 2024, with a projected growth trajectory that anticipates reaching around $13 billion by 2034. This translates to a compound annual growth rate (CAGR) of about 6.1% over the 2025-2034 period.
https://exactitudeconsultancy.com/reports/66433/disposable-syringes-and-accessories-market
Blood Collection Mixer Market
The blood collection mixer market is valued at approximately $250 million in 2024 and is projected to reach around $400 million by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of about 5.1% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66297/blood-collection-mixer-market
Hemochromatosis Treatment Market
The global hemochromatosis treatment market is valued at approximately $2.1 billion in 2024. The market is anticipated to grow significantly, reaching an estimated $3.5 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period of 2025–2034.
https://exactitudeconsultancy.com/reports/66046/hemochromatosis-treatment-market
Gestational Trophoblastic Disease Market
The gestational trophoblastic disease (GTD) market is currently valued at approximately $1.8 billion in 2024, with projections indicating a potential growth to around $3.1 billion by 2034. This represents a compound annual growth rate (CAGR) of approximately 6.2% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66033/gestational-trophoblastic-disease-market
Septicemia Diagnostic Market
The global septicemia diagnostics market is valued at approximately $1.5 billion in 2024, with projections indicating a growth to around $2.9 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 7.5% for the period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66018/septicemia-diagnostic-market
Single Use Safety Lancet Market
The global market for single-use safety lancets, valued at approximately $1.2 billion in 2024, is expected to reach around $2.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65995/single-use-safety-lancet-market
Microalbuminuria Test Strip Market
The microalbuminuria test strip market is poised for notable growth, valued at approximately $1.2 billion in 2024. This market is projected to expand to around $2.4 billion by 2034, indicating a robust growth trajectory. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 7.3%.
https://exactitudeconsultancy.com/reports/65977/microalbuminuria-test-strip-market
Monkeypox Virus Detection Reagent Market
The monkeypox virus detection reagent market is anticipated to reach approximately $150 million in value by 2024, driven by heightened awareness and diagnostic needs amid ongoing public health surveillance. The market is projected to expand significantly, reaching an estimated $300 million by 2034, reflecting sustained interest in infectious disease diagnostics and preparedness.
https://exactitudeconsultancy.com/reports/65957/monkeypox-virus-detection-reagent-market
Blood Tester Market
The global blood testing market is anticipated to reach a value of approximately $75 billion in 2024, driven by increasing prevalence of chronic diseases, rising health awareness, and advancements in diagnostic technologies. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% from 2025 to 2034, potentially reaching over $135 billion by 2034.
https://exactitudeconsultancy.com/reports/65953/blood-tester-market
HBsAg ELISA Test Kit Market
The HBsAg ELISA Test Kit market is poised for robust growth, with a current market value estimated at approximately $1.5 billion in 2024. Driven by the increasing global prevalence of Hepatitis B, ongoing advancements in diagnostic technologies, and rising healthcare expenditures, the market is projected to reach around $2.8 billion by 2034. This trajectory indicates a Compound Annual Growth Rate (CAGR) of approximately 6.5% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65911/hbsag-elisa-test-kit-market
Blood Plasma Extractor Market
The global blood plasma extractor market is valued at approximately $1.2 billion, driven by rising demand for plasma-derived therapies in treating various diseases. The market is projected to reach about $2.9 billion by 2034, reflecting an impressive Compound Annual Growth Rate (CAGR) of approximately 9.2% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65869/blood-plasma-extractor-market
Amphetamine Test Kit Market
The amphetamine test kit market is projected to reach a value of approximately $500 million in 2024, with expectations to grow to around $900 million by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 6% during the forecast period of 2025 to 2034.
https://exactitudeconsultancy.com/reports/65902/amphetamine-test-kit-market
CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@exactitudeconsultancy.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
11 minutes ago
- Chicago Tribune
Observation deck operator in former John Hancock Center plans major expansion and a new ‘immersive experience'
The operator of the 360 Chicago observation deck near the top of the former John Hancock Center said the attraction is taking over two additional floors, creating the city's first multilevel observation deck, a new three-story atrium and a 14,000-square-foot private event space. It's an encouraging sign for the Magnificent Mile, a retail district that has a lot of empty storefronts. Magnicity, the French company that owns 360 Chicago, last year bought the 95th and 96th floors, directly above the 94th-floor observation deck, after the abrupt closure of the legendary Signature Room restaurant and the Signature Lounge, both top tourist spots for decades. 'We are now positioned to bring much-needed investment into these iconic spaces, delivering an experience that truly reflects the historic and architectural significance of this incredible building,' said Nichole Benolken, managing director at 360 Chicago. Although 360 Chicago didn't provide many details about what visitors will experience in the expanded observation deck, it did drop a few hints. WB-Immersive, a global firm that helped design the opening ceremonies for the 2024 Paris Olympics and the 2024 Paralympics, will create an immersive experience for visitors in the renovated spaces, which will also include new exhibits and attractions. 'I can't say too much because we are still in the conceptual design phase,' said Pierre-Antoine Batail, WB-Immersive's head of creative strategy. It's certain that the space will no longer host a restaurant, Benolken said. Immersive retail experiences, such as the new interactive exhibit dedicated to Harry Potter at 676 N. Michigan Ave., have become popular in downtown Chicago, and for many spaces now make more financial sense than restaurants. 'Our decision making was data- and research-driven,' she said. 'The dining scene in Chicago has evolved dramatically in the past 30 years.' The Signature Room closed in September 2023. Its shutdown was a blow to the Magnificent Mile, where the retail vacancy rate soared as a result of online shopping trends and the pandemic. A message posted to the restaurant's social media pages cited COVID-19 and subsequent 'severe economic hardship.' Magnicity invested about $17 million into the former John Hancock Center, the skyscraper now known as 875 North Michigan Avenue, after buying the 94th floor more than 10 years ago. It added attractions such as Tilt, a moving glass ledge that for two minutes dangles guests more than 1,000 feet above the street, and CloudBar, the highest bar in Chicago. Nearly 1 million people visit the observation deck each year, a roughly 60% boost from when Magnicity took over, Benolken said. The company operates similar attractions atop buildings in Berlin, Paris and Rotterdam, Netherlands. The three-floor reconstruction will take 18 to 24 months to complete, and is the most significant interior renovation in the building's 56-year history, said Scott Duncan, design partner at SOM, the architectural firm that designed the 100-story John Hancock Center and leads the current project. SOM plans to connect all three floors with a grand staircase, replace all the windows on the 94th, 95th and 96th floors, providing visitors with much clearer views, and transform the 96th floor into a private event space, he said. That will also raise the profile of 875 North Michigan Avenue, hopefully attracting the many office users seeking spaces in the city's top trophy buildings. 'People are now looking for something out of the ordinary when it comes to office space,' Duncan said. 'And the real pyrotechnics will come when the (observation deck's) new exhibits are revealed.'
Yahoo
16 minutes ago
- Yahoo
RFK Jr. appoints 8 new members to CDC's vaccine advisory committee, including some critics of shots
Health and Human Services Secretary Robert F. Kennedy Jr. announced on Wednesday eight new members to the Centers for Disease Control and Prevention's independent vaccine advisory committee, some of whom have been critics of shots -- especially during the COVID-19 pandemic. It comes just two days after Kennedy removed all 17 sitting members of the Advisory Committee on Immunization Practices (ACIP), claiming the panel was plagued by conflicts of interest and was a "rubber stamp" for all vaccines. The ACIP makes recommendations on the safety, efficacy and clinical need of vaccines, and the CDC has the final say on whether or not to accept the recommendations. MORE: What may be next for CDC's vaccine advisory committee after RFK Jr. removed all its members? Kennedy said in a post on X that the new members include "highly credentialed scientists, leading public-health experts, and some of America's most accomplished physicians. All of these individuals are committed to evidence-based medicine, gold-standard science, and common sense." The new members will be at an upcoming ACIP meeting scheduled to be held between June 25 and June 27, according to Kennedy. The meeting is to discuss new recommendations for several vaccines, including the HPV vaccine and the COVID-19 vaccine. "The committee will review safety and efficacy data for the current schedule as well," Kennedy wrote in the post on X. The new eight members appear to have strong credentials related to medicine, public health, epidemiology and statistics, but with less of an emphasis on credentials related to immunology, virology and vaccinology in comparison with previous committees. Kennedy told ABC News on Tuesday that the replacements for ACIP would not be "anti-vaxxers." However, some of the new members have previously espoused anti-vaccine sentiments, especially around COVID-19 vaccines and mRNA technology. One of them, Dr. Robert Malone -- who made some early contributors to mRNA vaccine technology -- spread misinformation during the COVID-19 pandemic, claiming people were "hypnotized" into believing mainstream ideas about COVID-19, such as vaccination. MORE: RFK Jr. has promoted 'freedom of choice' while limiting vaccines, food Retsef Levi, another newly appointed member, has previously published non-peer reviewed research alongside Florida Surgeon General Dr. Joseph Ladapo on COVID-19 vaccines, suggesting healthy people have died from the shots. Another of the new members, Dr. Martin Kulldorff, was a co-author of the Great Barrington Declaration, along with Dr. Jay Bhattacharya, director of the National Institutes of Health. Published in October 2020 and named after the Massachusetts town in which it was drafted, the Great Barrington Declaration called for COVID-19 lockdowns to be avoided and a new plan for handling the pandemic by protecting the most vulnerable individuals but allowing most to resume normal activities, achieving herd immunity naturally -- a plan criticized as "unethical" by Dr. Tedros Adhanom Ghebreyesus, director-general of the World Health Organization. At least four of the eight members appear to have been influential to Kennedy's beliefs. Stat News reported that Malone, Kuldorff and two other new members, Vicky Pebsworth and Dr. Cody Meissner, are all listed in the dedication in the secretary's book, 'The Real Anthony Fauci,' which attempts to undermine the former health official's work and questions his motivations before and during the pandemic. It remains unclear if Kennedy plans to appoint any more members to ACIP RFK Jr. appoints 8 new members to CDC's vaccine advisory committee, including some critics of shots originally appeared on
Yahoo
21 minutes ago
- Yahoo
US immigration raid of Omaha meat plant cuts staff, fuels food production worries
By Tom Polansek CHICAGO (Reuters) -U.S. meat producer Glenn Valley Foods was operating an Omaha, Nebraska, facility with about 30% of its staff on Wednesday after federal agents detained workers in an immigration raid the previous day, slashing the output of products it sells to grocery stores and restaurants, the company's president said. In the wake of Tuesday's sweep by U.S. Immigration and Customs Enforcement agents, livestock traders and market analysts expressed concerns that the potential deportation of undocumented workers from such raids could disrupt U.S. food production at a time when beef prices have soared and meat processors report a labor shortage. ICE agents detained about 74 to 76 workers out of roughly 140 at the Glenn Valley Foods plant, President Chad Hartmann said. Other workers did not show up on Wednesday because they felt afraid or traumatized, he said, adding that the facility's production dropped to about 20% of normal. Glenn Valley Foods sells steak, chicken and corned beef products to restaurants and grocery stores, according to its website. Retail beef prices have set records as the size of the U.S. cattle herd has declined to its lowest level in 70 years after a years-long drought raised feed costs. Consumer demand for steaks and hamburgers has stayed strong nevertheless. Glenn Valley Foods is trying to determine how long it will take to hire new employees, Hartmann said. "The hole that got punched into our business is staffing," he said. Livestock traders worried that immigration raids could slow meat companies' demand to buy cattle from farmers to process into beef, if the companies do not have enough workers. Chicago Mercantile Exchange cattle futures came under pressure on Tuesday during the raid, after recently hitting records. "There's certainly going to be nervousness out there on where the labor situation goes, going forward," said Matt Wiegand, a commodity broker for risk management firm FuturesOne in Nebraska. Meatpackers still face an acute worker shortage, said Julie Anna Potts, president of the Meat Institute industry group. It worsened during the COVID-19 pandemic, when major companies such as Tyson Foods temporarily shut plants because of a lack of workers. Glenn Valley used E-Verify, a federal database used for checking employees' immigration status. Hartmann said Homeland Security told him on Wednesday that there was no better system. "We will have to continue to use it," he said. ICE said a criminal investigation was ongoing into what immigration officials called a large-scale employment of immigrants who are present in the U.S. illegally. Footage of the Glenn Valley raid released by ICE showed agents searching the plant, restraining workers' hands and ankles, and taking them into custody. ICE officers have been intensifying efforts in recent weeks to deliver on U.S. President Donald Trump's agenda of record-level deportations. Tensions boiled over in Los Angeles over the weekend when protesters took to the streets after ICE arrested migrants at Home Depot stores, a garment factory and a warehouse, according to rights advocates. On Tuesday night, demonstrators marched in New York, Atlanta and Chicago. More than half of all meatpacking workers in the U.S. are immigrants, according to the Center for Economic and Policy Research, a think tank. The Omaha World-Herald newspaper said on Tuesday that raids were also reported at local plants run by large meatpackers Tyson and JBS USA. Tyson and JBS told Reuters their facilities were not raided.
